Cargando…

Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies

Cancer cells reprogram their metabolism to meet bioenergetics and biosynthetic demands. The first observation of metabolic reprogramming in cancer cells was made a century ago (“Warburg effect” or aerobic glycolysis), leading to the classical view that cancer metabolism relies on a glycolytic phenot...

Descripción completa

Detalles Bibliográficos
Autores principales: Reyes-Castellanos, Gabriela, Masoud, Rawand, Carrier, Alice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460249/
https://www.ncbi.nlm.nih.gov/pubmed/32756381
http://dx.doi.org/10.3390/biomedicines8080270
_version_ 1783576558630338560
author Reyes-Castellanos, Gabriela
Masoud, Rawand
Carrier, Alice
author_facet Reyes-Castellanos, Gabriela
Masoud, Rawand
Carrier, Alice
author_sort Reyes-Castellanos, Gabriela
collection PubMed
description Cancer cells reprogram their metabolism to meet bioenergetics and biosynthetic demands. The first observation of metabolic reprogramming in cancer cells was made a century ago (“Warburg effect” or aerobic glycolysis), leading to the classical view that cancer metabolism relies on a glycolytic phenotype. There is now accumulating evidence that most cancers also rely on mitochondria to satisfy their metabolic needs. Indeed, the current view of cancer metabolism places mitochondria as key actors in all facets of cancer progression. Importantly, mitochondrial metabolism has become a very promising target in cancer therapy, including for refractory cancers such as Pancreatic Ductal AdenoCarcinoma (PDAC). In particular, mitochondrial oxidative phosphorylation (OXPHOS) is an important target in cancer therapy. Other therapeutic strategies include the targeting of glutamine and fatty acids metabolism, as well as the inhibition of the TriCarboxylic Acid (TCA) cycle intermediates. A better knowledge of how pancreatic cancer cells regulate mitochondrial metabolism will allow the identification of metabolic vulnerabilities and thus novel and more efficient therapeutic options for the benefit of each patient.
format Online
Article
Text
id pubmed-7460249
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74602492020-09-02 Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies Reyes-Castellanos, Gabriela Masoud, Rawand Carrier, Alice Biomedicines Review Cancer cells reprogram their metabolism to meet bioenergetics and biosynthetic demands. The first observation of metabolic reprogramming in cancer cells was made a century ago (“Warburg effect” or aerobic glycolysis), leading to the classical view that cancer metabolism relies on a glycolytic phenotype. There is now accumulating evidence that most cancers also rely on mitochondria to satisfy their metabolic needs. Indeed, the current view of cancer metabolism places mitochondria as key actors in all facets of cancer progression. Importantly, mitochondrial metabolism has become a very promising target in cancer therapy, including for refractory cancers such as Pancreatic Ductal AdenoCarcinoma (PDAC). In particular, mitochondrial oxidative phosphorylation (OXPHOS) is an important target in cancer therapy. Other therapeutic strategies include the targeting of glutamine and fatty acids metabolism, as well as the inhibition of the TriCarboxylic Acid (TCA) cycle intermediates. A better knowledge of how pancreatic cancer cells regulate mitochondrial metabolism will allow the identification of metabolic vulnerabilities and thus novel and more efficient therapeutic options for the benefit of each patient. MDPI 2020-08-03 /pmc/articles/PMC7460249/ /pubmed/32756381 http://dx.doi.org/10.3390/biomedicines8080270 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Reyes-Castellanos, Gabriela
Masoud, Rawand
Carrier, Alice
Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title_full Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title_fullStr Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title_full_unstemmed Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title_short Mitochondrial Metabolism in PDAC: From Better Knowledge to New Targeting Strategies
title_sort mitochondrial metabolism in pdac: from better knowledge to new targeting strategies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7460249/
https://www.ncbi.nlm.nih.gov/pubmed/32756381
http://dx.doi.org/10.3390/biomedicines8080270
work_keys_str_mv AT reyescastellanosgabriela mitochondrialmetabolisminpdacfrombetterknowledgetonewtargetingstrategies
AT masoudrawand mitochondrialmetabolisminpdacfrombetterknowledgetonewtargetingstrategies
AT carrieralice mitochondrialmetabolisminpdacfrombetterknowledgetonewtargetingstrategies